A recent study reveals that people who come off new slimming jabs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who stop traditional diet and exercise plans.
Published data in a major health publication shows that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying such drugs should be aware of the potential of rapid weight regain when the treatment ends," stated expert Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment weight within about a year and a half.
Analyzing Therapies
The research, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with conventional dieting.
The team emphasize that individuals who shed pounds through diet and exercise typically experience a less rapid weight regain—around 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts believe the mode of action of the jabs accounts for the heightened weight return.
These medications copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Issue?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals contend that, considering the significant potential of relapse, the therapy is often ongoing.
This perspective is supported by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," comparing it to managing diseases like diabetes.
User Testimonies
Users who have come off the medication report a intense return of cravings.
"It felt as if a switch flipping and I was suddenly extremely hungry," said an individual.
The struggle is compounded if patients have not developed lasting dietary or behavioural modifications during therapy.
Widespread Use
Figures show that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is greater among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated lifestyle management.
